Shares of NPS Pharmaceuticals Inc. jumped 31.5 percent on positive Phase III data for GLP-2 analogue Gattex (teduglutide) in short bowel syndrome (SBS), and the Bedminster, N.J.-based firm expects to submit a new drug application in the second half of this year.